Sooma Medical revealed on Friday that it has passed the US patent for its new stimulation electrode for safe and effective delivery of all neuromodulation therapies.

The company added that its electrode technology reduces the resistance in the skin-electrode interface when compared to competing solutions as well as faster patient preparation and superior accuracy in delivery of the stimulation dose. The hydrophilic properties of the material ensure stable contact for extended periods of time.

This neuromodulation technology is the result of a long term research project with industrial and academic partners finally reaching product stage. Since the launch, more than 1000 patients worldwide have received Sooma tDCS treatment in more than 20.000 treatment sessions.

Under its IP portfolio, the company now strengthens its position as the leading provider of home-based neuromodulation solutions with a unique product portfolio. Sooma tDCS is a therapy product using weak electrical stimulation and is intended for the treatment of major depressive disorder (MDD), chronic pain and fibromyalgia.

In addition, the company has obtained regulatory approvals for the product in the EU (Class IIa), Canada, Mexico, Singapore, Australia, Malaysia, Indonesia, and Turkey. In the US, the US FDA limits the use of the tDCS for investigational use only. Its products are distributed in over 30 countries.